Disposition of 5000000 shares by Dicicco Wendy F of Akari Therapeutics at 0.0017 subject to Rule 16b-3

Slightly above 67% of Akari Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Akari Therapeutics PLC stock suggests that many investors are alarmed at this time. Akari Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Akari Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Akari Therapeutics PLC Officer Interim Cfo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 5000000 stock option (right to buy) at 0.0017 of Akari Therapeutics by Dicicco Wendy F on 24th of June 2024. This event was filed by Akari Therapeutics PLC with SEC on 2024-07-17. Initial filing of beneficial ownership - SEC Form 3

Akari Therapeutics Fundamental Analysis

We analyze Akari Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akari Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akari Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

Akari Therapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Akari Therapeutics PLC Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Akari Therapeutics stock to make a market-neutral strategy. Peer analysis of Akari Therapeutics could also be used in its relative valuation, which is a method of valuing Akari Therapeutics by comparing valuation metrics with similar companies.

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.